ARTICLE | Distillery Therapeutics


December 5, 2017 7:32 PM UTC

Cell culture and mouse studies suggest RvD1, RvD2 and RvE1 could help treat solid tumors. In a mouse model of lung cancer and a xenograft model of pancreatic cancer, intraperitoneal injection of RvD1, RvD2 or RvE1 decreased tumor growth compared with vehicle. Also in the models, RvE1 plus gemcitabine, Erbitux cetuximab or Tarceva erlotinib decreased tumor volume compared with any agent alone. In mouse models of metastatic lung cancer and metastatic melanoma, RvD1 or RvD2 decreased the number of lung metastases compared with vehicle. In a mouse model of breast cancer, RvD1 plus cisplatin decreased tumor volume compared with either agent alone. Next steps include a clinical trial of select resolvins in undisclosed solid tumors.

The generic nucleoside analog gemcitabine is marketed to treat non-small cell lung cancer (NSCLC) and breast, ovarian and pancreatic cancers...